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Abstract The adenosine receptor agonist 2-[p-(2-carbox-
yethyl)phenylethylamino]-5′-N-ethylcarboxamidoadeno-
sine (CGS 21680) is generally considered to be a selective
adenosine A2A receptor ligand. However, the compound
has previously been shown to exhibit binding character-
istics that are not compatible with adenosine A2A receptor
binding, at least in brain regions other than the striatum.
We have examined binding of [3H]CGS 21680 and of
antagonist radioligands with high selectivity for adenosine
A1 or A2A receptors to hippocampus and striatum of mice
lacking either adenosine A1 (A1R
(−/−)) or A2A (A2AR
(−/−))
receptors. Both receptor autoradiography and membrane
binding techniques were used for this purpose and gave
similar results. There were no significant changes in the
binding of the A1 receptor antagonist [
3H]DPCPX in mice
lacking A2A receptors, or in the binding of the A2A
receptor antagonists [3H]SCH 58261 and [3H]ZM 241385
in mice lacking A1 receptors. Furthermore, [
3H]CGS
21680 binding in striatum was abolished in the A2AR(−/−),
and essentially unaffected in striatum from mice lacking
A1 receptors. In hippocampus, however, binding of [
3H]
CGS 21680 remained in the A2AR(−/−), whereas binding
was virtually abolished in the A1R(−/−). There were no
adaptive alterations in A2A receptor expression in this
region in A1R(−/−) mice. Thus, most of the [3H]CGS
21680 binding in hippocampus is dependent on the
presence of adenosine A1 receptors, but not on A2A
receptors, indicating a novel binding site or novel binding
mode.
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Abbreviations CGS 21680: 2-[p-(2-Carboxyethyl)
phenylethylamino]-5′-N-ethylcarboxamidoadenosine . ZM
241385: 4-(2-[7-Amino-2-(2-furyl)[1,2,4]triazolo[2,3-a]
[1,3,5]triazin-5-ylamino]ethyl)phenol . SCH 58261: 5-
Amino-7-(2-phenylethyl)-2-(2-furyl)-pyrazolo[4,3-e]-
1,2,4-triazolo[1,5-c]pyrimidine . DPCPX: 1,3-Dipropyl-8-
cyclopentylxanthine . CGS 15943: 9-Chloro-2-(2-
furanyl)-5,6-dihydro-[1,2,4]-triazolo-[1,5]quinazolin-5-
imine monomethanesulfonate . NECA: 5′-N-
ethylcarboxamidoadenosine . A1R(−/−): Adenosine A1
receptor knock-out . A1R(+/−): Adenosine A1 receptor
heterozygote . A1R(+/+): Adenosine A1 receptor wild-type .
A2AR(−/−): Adenosine A2A receptor knock-out .
A2AR(+/−): Adenosine A2A receptor heterozygote .
A2AR(+/+): Adenosine A2A receptor wild-type . RT-PCR:
Reverse transcriptase-polymerase chain reaction
Introduction
Pharmacological tools are indispensable in the classifica-
tion of receptors. However, the specificity of these
pharmacological tools is often not completely certain.
One interesting way of ascertaining the specificity (or lack
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thereof) of pharmacological tools is to use mice with a
targeted disruption of genes coding for the purported drug
target. Here we have used this approach to elucidate some
questions that relate to a drug commonly used to study
adenosine receptors.
There are four cloned and pharmacologically character-
ized adenosine receptors, A1, A2A, A2B, and A3 (Fredholm
et al. 2001). To study the role of A2A receptors, the agonist
2-[p-(2-carboxyethyl)phenylethylamino]-5′-N-ethylcar-
boxamidoadenosine (CGS 21680) has been widely used
ever since it was discovered more than 10 years ago
(Hutchison et al. 1989; Jarvis et al. 1989). For example, it
proved very useful in demonstrating the high density of
adenosine A2A receptors in the striatum (Jarvis and
Williams 1989; Parkinson and Fredholm 1990). CGS
21680 potently stimulated cAMP formation in striatum but
had no significant effect in hippocampus (Lupica et al.
1990; Lopes et al. 1999b). When used at high concentra-
tions, however, it could be shown to inhibit synaptic
transmission in hippocampus, suggesting an effect at
adenosine A1 receptors (Lupica et al. 1990). At much
lower concentrations, CGS 21680 stimulated the release of
acetylcholine from hippocampus (Cunha et al. 1994b,
1995; Jin and Fredholm 1997; Rebola et al. 2002), and
increased synaptic transmission modestly, particularly in
the presence of an adenosine A1 receptor ligand (Cunha et
al. 1994a). Interestingly, the compound’s ability to
facilitate hippocampal synaptic transmission in young
adult rats was completely dependent on concomitant
pharmacological stimulation of adenosine A1 receptors
(Lopes et al. 2002).
Studies on CGS 21680 binding to extrastriatal sites also
suggest peculiar properties. Whereas, binding of this
agonist to striatum exhibits pharmacology typical for the
adenosine A2A receptor, binding to hippocampus shows
atypical pharmacology (Johansson et al. 1993; Johansson
and Fredholm 1995). Detailed binding studies in the rat
show that [3H]CGS 21680 binds to two distinct sites in
both striatum and hippocampus (Cunha et al. 1996, 1999).
Thus, in striatum more than 80% and in hippocampus less
than 20% of the [3H]CGS 21680 binding show typical
A2A pharmacology, whereas the remaining sites show high
affinity also for adenosine A1 receptor agonists and
antagonists; for example, at these “atypical” binding
sites 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) could
potently displace [3H]CGS 21680 (Cunha et al. 1996). By
contrast, CGS 21680 can only displace a small proportion
of [3H]DPCPX bound to hippocampus (Lopes et al. 2002).
These data indicate a possible functional link between
adenosine A1 and A2A receptors in hippocampus. The
background for such an interaction is not clear, but the
data presented here obtained using mice with targeted
deletions of adenosine A1 (A1R
(−/−)) and A2A receptors
(A2AR(−/−)), suggest that a major explanation is that in
hippocampus [3H]CGS 21680 interacts not with adenosine
A2A but, directly or indirectly, with A1 receptors.
Materials and methods
Mice We used mice genetically modified to be deficient in
different adenosine receptors. Adenosine A1 receptor
deficient mice were on a mixed 129/OlaHsd/C57BL/6
background generated as described (Johansson et al.
2001). Heterozygous animals of the third generation
were bred and all experiments were conducted on litter
mates genotyped using PCR and/or Southern blot. Aden-
osine A2A receptor deficient mice, generated as described
(Ledent et al. 1997), were on a pure CD1 background.
Homozygous animals of the tenth generation were bred to
produce offspring with each genotype (controlled using
PCR as described; Snell et al. 2000). Animal experimental
procedures were approved by Stockholm’s Northern
animal ethics board (Stockholms norra djurförsöksetiska
nämnd), N43/98.
Drugs and chemicals 2-p-(2-Carboxyethyl[3H]N-phe-
nethylamino-5′-ethylcarboxamidoadenosine ([3H]CGS
21680, specific activity 41–43 Ci/mmol) and 8-cyclopen-
tyl (2,3-[3H]N)-1,3-dipropylxanthine ([3H]DPCPX, spe-
cific activity 116.0 Ci/mmol) were from DuPont NEN,
Stevenage, UK; [3H]5-amino-7-(2-phenylethyl)-2-(2-
furyl)-pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine
([3H]SCH 58261, specific activity 77 Ci/mmol) was a kind
gift from Dr Ennio Ongini, Schering-Plough, Milan, Italy;
(±)N6-R-phenylisopropyladenosine (R-PIA) was from
Sigma, Poole, UK; adenosine deaminase (ADA, calf
intestine suspension, 200 U/mg, EC 3.5.4.4) from Roche,
Germany; 9-chloro-2-(2-furanyl)-5,6-dihydro-[1,2,4]-tria-
zolo-[1,5]quinazolin-5-imine monomethanesulfonate
(CGS 15943) was from Research Biochemical Interna-
tional, Natick, MA, USA; 2-chloroadenosine and 5′-N-
ethylcarboxamidoadenosine (NECA) were from Sigma,
Sweden; and 4-(2-[7-amino-2-(2-furyl)[1,2,4]triazolo[2,3-
a][1,3,5]triazin-5-ylamino]ethyl)phenol ([3H]ZM 241385
specific activity 17 Ci/mmol) was from Tocris, Bristol,
UK. All other reagents were of the highest purity
available.
Analysis of mRNA with reverse transcriptase-polymerase
chain reaction After brief CO2 anesthesia A1R
(+/+),
A1R(−/−), and A2AR(−/−) mice were decapitated. The
striata and hippocampi were dissected out. Total RNA of
each sample was extracted by means of RNeasy RNA
extraction kit (Qiagen, Hilden, Germany). RNA was
transcribed to cDNA using random hexamers and MuLV
reverse transcriptase. Products were thereafter amplified
by means of PCR using the adenosine A2A receptor
specific primers 5′-CTC CAC CAT GAT GTA CAC CG 3′
and 5′-CAT GGT TTC GGG AGA TGC AG 3′. The
cDNA obtained from the A2AR(−/−) served as a negative
control. PCR products were analyzed with agarose gel
electrophoresis, DNA visualized by ethidium bromide
staining and photographed with a video camera.
In another set of experiments, the cDNA was used for
semi-quantitative real-time PCR (Heid et al. 1996) in an
ABI Prism 7000 Sequence Detector System (Applied
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Biosystems). The β-actin and subtype-specific (A1 and
A2A) adenosine receptor primers and probes (MWG-
Biotech AG, Ebersberg, Germany) used were synthesized
according to sequences previously published (Chunn et al.
2001). The real time PCR reactions were prepared using
the TaqMan Universal PCR master mix (Applied Biosys-
tems) and probes labeled at the 5′-end with the reporter
dye 6-carboxy-fluorescein (FAM) and at the 3′-end with
the quencher dye 6-carboxytetramethyl-rhodamine
(TAMRA). The passive reference dye ROX was added
to adjust for background variability and for differences in
detection sensitivity.
Ligand binding to membranes Groups of between three
and five mice of each genotype were killed by decapitation
after brief CO2 anesthesia. The brains were removed and
the hippocampi and striata were dissected out at 4°C in
sucrose solution (0.32 M) containing 2 mM EGTA,
50 mM Tris–HCl (pH 7.6). Membranes were prepared
(Cunha et al. 1996) by homogenization in a Potter-
Elvehjem homogenizer followed by centrifugation at
1,000 g for 10 min and 14,000 g for 12 min at 4°C. The
pellets were then resuspended in a solution containing
50 mM Tris–HCl (pH 7.4), 2 mM EGTA, 1 mM EDTA,
2 U/ml ADA and incubated for 30 min at 37°C to remove
endogenous adenosine. The mixture was then centrifuged
at 14,000 g for 10 min at 4°C and the pellets resuspended
in the incubation solution containing 50 mM Tris–HCl
(pH 7.4) and 10 mM MgCl2 (for [
3H]CGS 21680 binding
experiments) or 2 mM MgCl2 (for [
3H]DPCPX binding
experiments). The protein concentration was determined
using the Bio-Rad protein assay.
In the binding experiments, 280–331 μg of membrane
protein was incubated with [3H]CGS 21680 (0.1–20 nM)
for 4 h in a final volume of 300 μl in an incubation
solution containing 50 mM Tris–HCl (pH 7.4), 10 mM
MgCl2, and 4 U/ml ADA. Due to the large amount of
tissue required, in some of the experiments only 3–5 [3H]
CGS 21680 concentration values were tested within the
range previously described. Specific binding was deter-
mined by subtraction of the non-specific binding, which
was measured in the presence of 1 μM CGS 15943. We
felt confident in the determination of non-specific binding
in these experiments since the results obtained match those
previously obtained in rat tissue with high concentrations
of different non-selective adenosine receptor ligands
(Johansson et al. 1993; Johansson and Fredholm 1995;
Cunha et al. 1996, 1999). All binding assays were
performed in duplicate. The binding reactions were
stopped by vacuum filtration through glass fiber filters
(filtermats for receptor binding from Skatron, Molecular
Devices, Sunnyvale, CA, USA) using a Skatron 1719 cell
harvester and a washing volume of 10 ml at 4°C. The
filters were then placed in scintillation vials with 4 ml of
scintillation liquid (Ready Safe; Beckman Coultier, Full-
erton, CA, USA). Radioactivity was determined after at
least 12 h, and the counting efficiency was 55–60%. To
ensure a counting error lower than 5% of counts, the
samples were counted for 10 min.
The specific binding from saturation experiments was
fitted by non-linear regression to a one-site binding graph
using the Raphson–Newton method (GraphPad software,
San Diego, CA, USA) to determine the binding parameters
(dissociation constant, Kd and maximal number of binding
sites, Bmax). Data are mean ± SEM values.
Receptor autoradiography The mice were anesthetized in
CO2 and then decapitated. Brains were immediately
dissected out, frozen on dry ice, and thereafter stored at
−80°C. Sections of 14 μm thickness were cut in a cryostat
+1.42 to +0.62 mm (striatal level), −0.34 to −0.58 mm
(globus pallidus level), and −1.70 to −2.18 mm (hippo-
campus level) from Bregma. Sections were mounted on
poly-L-lysine coated slides and stored at −20°C before use.
For detection of adenosine A1 receptors, slides were
incubated with 0.2, 0.5, 1, 2, 5, or 10 nM of the selective
receptor antagonist [3H] DPCPX with and without
100 μM guanosine triphosphate (GTP) as described in
details elsewhere (Fastbom and Fredholm 1990). For
evaluation of non-specific binding, the adenosine analogue
R-PIA (20 μM) was added to the incubation solution.
For detection of adenosine A2A receptors, slides were
incubated with 0.1, 0.3, 1, 3, or 10 nM of [3H]SCH 58261
(Fredholm et al. 1998) or with 2 nM [3H]ZM 241385 in
50 mM Tris–HCl solution (pH 7.4) containing adenosine
deaminase (2 U/ml). For estimation of non-specific
binding, the adenosine analogue NECA (50 μM) was
added.
[3H]CGS 21680 binding was determined using slides
incubated with 0.3, 1, 3, 10, or 30 nM [3H]CGS 21680 as
described previously (Johansson and Fredholm 1995). For
estimation of non-specific binding, the adenosine receptor
agonist 2-chloroadenosine (20 μM) was added to the
incubation solution. As previously mentioned, the simi-
larity of the results obtained in autoradiography and
membrane binding studies using different non-selective
adenosine receptor ligands to define non-specific binding
indicates that the ligand chosen here is not affecting the
conclusions drawn.
After incubation, dried sections were apposed to
3Hyperfilm (Amersham) together with tritium standards.
Optical densities were determined with an MCID M5
system (Imaging Research, St Catharines, ON, Canada)
and converted to fmol/mg tissue. Data were analyzed with
GraphPad Prism Software (San Diego, CA, USA).
Results
mRNA expression
We first confirmed the lack of adenosine A2A receptor
mRNA expression in our A2AR(−/−) mice by reverse
transcriptase-polymerase chain reaction (RT-PCR;
Fig. 1a). Using semi-quantitative real-time PCR analysis
(Fig. 1b), we show that A2A receptors are expressed in
hippocampus, in agreement with previous reports (Cunha
et al. 1994a; Dixon et al. 1996). However, the expression
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of A2A receptor mRNA in hippocampus was considerably
lower than that in striatum in both A1R(+/+) and A1R(−/−)
(Fig. 1b). Semi-quantitative real-time PCR analysis of
tissue obtained from the striatum of wild-type mice also
show that A2A mRNA is somewhat more abundant than
A1 mRNA. In contrast, in the hippocampus A1 was much
more abundant than A2A (the difference between A1 and
A2A mRNA is approximately 50-fold). The A1 knock-out
striatum and hippocampus expressed levels of A2A similar
to those found in wild-type tissue. As expected, no
adenosine A1 receptor mRNA signal was found in the
A1R(−/−) (Fig. 1b).
Binding of [3H]DPCPX
The first report of the A1R(−/−) mouse showed that [3H]
DPCPX binding was essentially eliminated in several
brain regions and was reduced to half in heterozygous
mice (Johansson et al. 2001). This result was confirmed
here as seen in Fig. 2. More importantly, there were no
clear-cut effects of knocking out the A2A receptor on [
3H]
DPCPX binding (see Fig. 2). This is in contrast with a
previous report of decreased DPCPX binding in the
hippocampus in A2AR(+/−), and increased binding in
A2AR(−/−) mice (Snell et al. 2000).
The mice used in the adenosine A1 and the A2A receptor
studies had different genetic backgrounds. Therefore, it is
important to note that there were no significant differences
in Kd and no major differences in Bmax in the different
mouse strains used here. The ratio of DPCPX binding in
presence and absence of GTP, thought to reflect the
extracellular adenosine concentration as well as the
coupling of the receptor to G proteins (Fastbom and
Fredholm 1990), showed no major differences between the
A1 and A2A genotypes used in this study (data not shown).
However, the effect could not be estimated in the A1R(−/−)
because of the lack of DPCPX binding.
Binding of [3H]SCH 58261 and [3H]ZM 241385
To study the distribution and expression of A2A receptors
in the mice, we used both the highly selective antagonist
radioligand [3H]SCH 58261 and the somewhat less
selective antagonist radioligand [3H]ZM 241385 (Ongini
et al. 1999). In accordance with previous autoradiographic
studies (Lindström et al. 1996; Fredholm et al. 1998), very
little specific binding was observed in any brain region
outside the striatum in wild-type mice (Fig. 3). As seen in
Fig. 3, the binding to adenosine A2A receptors in caudate
putamen and globus pallidus was entirely dependent on
the genotype, with no binding being present in A2AR(−/−)
mice and half the normal number of binding sites in
A2AR(+/−) mice. There were no compensatory changes in
[3H]SCH 58261 or [3H]ZM 241385 binding in mice with
no adenosine A1 receptors (Fig. 3).
Binding of [3H]CGS 21680
The agonist radioligand [3H]CGS 21680 also preferen-
tially bound to the striatal regions (Fig. 4), but some weak
binding was also seen in the cortex and hippocampus. We
confirm the previous finding (Ledent et al. 1997) that
binding of [3H]CGS 21680 in the striatum is abolished in
the A2AR(−/−) mice. Thus, quantification of the autoradio-
graphic binding experiments showed the expected changes
in [3H]CGS 21680 binding in caudate putamen and
nucleus accumbens of the A2AR(+/−) and A2AR(−/−)
mice (Fig. 5). For example, in the nucleus accumbens
the Bmax was 139 (127–150) fmol/mg (mean and 95%
confidence interval [CI] n=3) in the A2AR(+/+) mice, 74
(54–95) fmol/mg (n=5) in the A2AR(+/−) mice, and no
binding was detected in the A2AR(−/−) mice (n=4). There
were no differences in [3H]CGS 21680 binding in mice
with different expression of adenosine A1 receptors.
We and others have previously demonstrated the
existence of specific binding of [3H]CGS 21680 in
extrastriatal regions, although the binding density is
Fig. 1 Adenosine receptor mRNA expression in knock-out mice. a
Adenosine A2A receptor expression in the striatum in wild-type
(WT) and adenosine A2A receptor knock-out (KO) mice. No A2A
receptor message can be detected in the knock-out brain.
Representative reverse transcriptase-polymerase chain reaction
(RT-PCR) data from 1 out of 4 experiments are shown. The
experiment was performed in the presence (+) and in the absence (−)
of RT. b With semi-quantitative real-time PCR the A1 receptor
message appeared to be abundant in both striatum and hippocampus,
whereas no signal was detected in the adenosine A1 receptor knock-
out (A1R(−/−)). Similar levels of A2A receptor message were detected
in hippocampus in both wild-type (A1R(+/+) and A1R(−/−)), but at a
much lower level than in striatum. The RT-PCR reactions were
performed in triplicate. Values are expressed as the difference in the
number of cycles needed to reach the detection threshold (Ct = cycle
at threshold), using β-actin as reference
(Ct ¼ Ctadenosine receptor  Ctactin).
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considerably lower than that in the basal ganglia (Wan et
al. 1990; Johansson et al. 1993; Johansson and Fredholm
1995; Kirk and Richardson 1995; Cunha et al. 1996,
1999). This low abundance binding site is likely to
represent binding of [3H]CGS 21680 to adenosine receptor
(s) since it is displaced by several adenosine receptor
ligands, albeit with a profile that resembles more to A1
than to A2A receptors (Johansson et al. 1993; Johansson
and Fredholm 1995; Kirk and Richardson 1995; Cunha et
al. 1996, 1999). Since pharmacological characterization of
[3H]CGS 21680 binding with displacement curves failed
to provide a clear picture, we hoped that the use of A1 and
A2A receptor knock-out mice would provide a clear
answer to whether CGS 21680 binds to A1 or to A2A
receptors in the hippocampus. Indeed, our autoradio-
graphic studies showed that, in contrast to the basal
ganglia, [3H]CGS 21680 binding in the CA1 region of the
hippocampus was not affected by differences in the A2A
receptor genotype. Instead, there were marked differences
depending on the adenosine A1 receptor genotype (Figs. 4,
5). Binding to this hippocampal region was essentially
abolished in A1R(−/−) mice and reduced to half in A1R(+/−)
mice (Fig. 5). This finding was confirmed by binding
experiments using membranes prepared from striatum or
hippocampus of A1R(+/+) and A1R(−/−) mice (Table 1). In
the striatum, [3H]CGS 21680 bound with high affinity (Kd
approximately 2 nM), and binding was not significantly
different between the two genotypes. By contrast, in
hippocampal membranes from A1R(+/+) mice, Kd was at
least 10 times higher and in A1R(−/−) mice no binding at
all could be detected.
Discussion
The major finding of the present study is that the
hippocampal binding of the purportedly A2A receptor
selective agonist [3H]CGS 21680 is lost in animals that do
not express adenosine A1 receptors, despite the fact that
there is no indication of adenosine A2A receptor alterations
in such animals. Furthermore, in this area [3H]CGS 21680
binding instead remains in animals lacking adenosine A2A
receptors. These findings imply that, in some parts of the
brain, CGS 21680 binds, and acts, on targets other than
adenosine A2A receptors.
It has been repeatedly shown using many different
methods that adenosine A2A receptors are highly enriched
Table 1 Binding of [3H]CGS 21680 to striatal and hippocampal
membranes from wild-type (A1R(+/+)) and A1 receptor knock-out
mice (A1R(−/−)). Results are given as Bmax (fmol/mg protein; mean ±
SEM, n=1). The corresponding Kd values were, in the striatum, 1.99
±0.86 nM for A1R(+/+)s and for A1R(−/−)Kd was kept constant at
1.99 nM; in the hippocampus, 10.98±8.59 nM and 0.95±1.69 nM
for A1R(+/+) and A1R(−/−) respectively.
Tissue A1R(+/+) A1R(−/−)
Striatum 171±9 196±11
Hippocampus 59±22 −6±2
Fig. 2 Binding of [3H]DPCPX to sections of brain from A1 and
A2A receptor knock-out mice and their corresponding wild-types.
The upper four panels show representative autoradiograms obtained
using 10 nM [3H]DPCPX at the level of the striatum in mice. The
lower panel summarizes the results of binding experiments by
plotting the Bmax values in selected brain regions from experiments
using six different concentrations of [3H]DPCPX in 5–6 animals. In
the study of A1R(−/−), the Bmax values were 163 (150–176) fmol/mg
and 87 (78–97) fmol/mg gray matter (mean and 95% confidence
interval) in the striatum of A1R(+/+) and A1R(+/−) mice. The
corresponding Kd values were 0.43 (0.29–0.57) nM and 0.37 (0.20–
0.55) nM. No binding was detected in A1R(−/−) mice. The values in
CA1 were: Bmax 384 (360–408) fmol/mg and 218 (204–233) fmol/
mg gray matter; Kd 0.49 (0.37–0.63) nM and 0.44 (0.31–0.58) nM.
Again, no binding was observed in A1R(−/−) mice. The values in
CA3 were: Bmax 317 (277–358) fmol/mg and 185 (161–209) fmol/
mg gray matter; Kd 0.43 (0.19–0.67) nM and 0.32 (0.12–0.52) nM
for A1R(+/+) and A1R(+/−) respectively. No binding was observed in
A1R(−/−) mice. In the study of A2AR(−/−), the Bmax values in striatum
were: A2AR(+/+) 188 (166–209) fmol/mg; A2AR(+/−) 181 (166–
194) fmol/mg; and A2AR(−/−) 173 (155–192) fmol/mg gray matter.
The corresponding Kd values were: A2AR
(+/+) 0.39 (0.20–0.58) nM;
A2AR(+/−) 0.44 (0.29–0.58) nM; A2AR(−/−) 0.38 (0.20–0.56) nM. In
CA1 Bmax values were: A2AR
(+/+) 357 (299–416); A2AR(+/−) 341
(298–384); and A2AR(−/−) 325 (286–365). The corresponding Kd
values were: A2AR(+/+) 0.47 (0.15–0.79) nM; A2AR(+/−) 0.66
(0.35–0.98) nM; and A2AR(−/−) 0.44 (0.21–0.66) nM. In CA3 Bmax
values were: A2AR(+/+) 332 (279–384); A2AR(+/−) 321 (285–358);
and A2AR(−/−) 298 (260–336). The corresponding Kd values were:
A2AR(+/+) 0.56 (0.21–0.92) nM; A2AR(+/−) 0.69 (0.39–0.98) nM;
and A2AR(−/−) 0.47 (0.22–0.72) nM.
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in caudate putamen, nucleus accumbens and tuberculum
olfactorium, and that expression levels elsewhere are low
(Jarvis and Williams 1989; Parkinson and Fredholm 1990;
Cunha et al. 1994a; Dixon et al. 1996). Here we show that
there are no major changes in the density of adenosine A2A
receptors, measured with three different radioligands
including [3H]CGS 21680, in the areas of high expression
(i.e., basal ganglia), in mice that have a targeted deletion of
the adenosine A1 receptor. This implies that the expression
of A2A receptors is not critically dependent upon the
presence or absence of adenosine A1 receptors. This is in
accordance with the observation that the function of A2A
receptors does not seem to be markedly affected by
alterations in A1 receptors: caffeine actions on behavior
that are entirely dependent on blockade of A2A receptors in
striatum (Ledent et al. 1997; El Yacoubi et al. 2000) are
only marginally affected in animals that lack adenosine A1
receptors (Halldner et al. 2004).
On the other hand purportedly A2A receptor-mediated
actions in areas with low levels of A2A receptor expression
have been reported to be dependent on adenosine A1
receptors (O’Kane and Stone 1998; Lopes et al. 1999a,
2002; Cunha and Ribeiro 2000). For example, the effect of
CGS 21680 on glutamatergic transmission in hippocam-
pus of young adult rats appears to be strongly dependent
on the activity at adenosine A1 receptors (Lopes et al.
1999a, 2002). Furthermore, CGS 21680 attenuates the
neuronal inhibition achieved by an adenosine A1 receptor
Fig. 3 Binding of adenosine A2A receptor antagonist radioligands
to brains from A1R(+/+), A1R(+/−), A1R(−/−), A2AR(+/+), A2AR(+/−),
and A2AR(−/−) mice (n=3–6). Autoradiographic experiments were
performed as described under Materials and methods. Results are
expressed as binding at a concentration of 2 nM ligand (mean ±
SEM). In the upper panels, autoradiograms with SCH 58261 and
ZM 241385 binding in a wild-type animal are shown. The non-
specific binding is shown to the right in the autoradiograms. The
lower left panel summarizes the results of [3H]SCH 58261 binding
to sections. There are no significant differences in binding in the
caudate between A1R(+/+), A1R(+/−), and A1R(−/−) mice. The
A2AR(−/−) mice did not show detectable specific binding of [3H]
SCH 58261 in the caudate. The A2AR(+/−) showed an approximately
50% reduction in binding (caudate: 134.5 fmol/mg gray matter, 95%
confidence interval (CI) 107.5–161.5) compared with the A2AR(+/+)
mice (caudate: 287.9 fmol/mg gray matter, CI 219.4–356.4).
However, the binding in CA1 did not significantly differ from
zero in any genotype. (The reason for the negative values is that
non-specific binding with SCH 58261 is high.) The lower right
panel shows similar results using [3H]ZM 241385 as the radioli-
gand. In the A2AR(+/−), binding in the caudate was reduced to
approximately half compared with wild-type animals. There was no
detectable binding in A2AR(−/−) mice (in fact the sections could not
be distinguished from the background) and therefore the values are
zero. No [3H]ZM 241385 binding was detected in the hippocampus
in any genotype. n.s. non-specific binding
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agonist in the hippocampus (Cunha et al. 1994a; O’Kane
and Stone 1998). This was taken as evidence for
interactions between the two receptor subtypes. The
present finding that [3H]CGS 21680 binding in hippo-
campus is virtually lost in mice lacking A1 receptors
provides an alternative explanation; agents that are
presumed to act solely on A2A receptors may in fact also
interact with A1 receptors. The functional antagonistic
interaction between A1 receptor agonists and CGS 21680
that has been repeatedly observed could then be explained
if CGS 21680 competes with the binding of A1 agonists or
antagonists. However, CGS 21680 was originally devel-
oped as a selective agonist precisely because of its lack of
interference, at reasonably low concentrations, with the
binding of A1 agonists or antagonists. Indeed, the
previously mentioned study (Lopes et al. 2002) confirmed
that CGS 21680 does not interfere significantly with the
binding of the A1 agonist CPA. It was also shown that
under conditions favoring CGS 21680 binding (high
magnesium) CGS 21680 displaces DPCPX binding only
at high concentrations (IC50 values approximately 1 μM)
in most brain regions, supporting a low affinity to the
adenosine A1 receptor. In contrast, in the same study, 30%
of the DPCPX displacement in the CA1 region had an IC50
Fig. 4 Typical autoradiograms at a concentration of 30 nM [3H]
CGS 21680 with wild-types on the left and knock-outs on the right.
Sections are at a level where the posterior part of the caudate
putamen together with globus pallidus can be seen as well as the
most anterior part of the hippocampus (arrows); the heavier the
labeling the darker the image. It is readily seen that the labeling in
caudate and in globus pallidus is much stronger than that seen
elsewhere, and that this difference is lost in the A2AR(−/−) mice.
Note that it is also easier to discern the contours of the hippocampus
in the slices that possess adenosine A1 receptors.
Fig. 5 Binding of [3H]CGS 21680 to brains from A1R(+/+),
A1R(+/−), A1R(−/−), A2AR(+/+), A2AR(+/−), and A2AR(−/−) mice
(n=5–6). The two top panels show the results of saturation binding
to caudate putamen (CP) in sections. It is readily seen that the
binding of [3H]CGS 21680 in this region is dependent on A2A
receptor genotype. In the two lower panels, it can be seen that this is
not the case for the binding of [3H]CGS 21680 to the hippocampus.
As binding did not saturate within the concentration range studied
(and because non-specific binding became intolerably high at still
higher concentrations) results from two concentrations (3 nM and
30 nM) of [3H]CGS 21680 are shown. It is seen that the binding is
strongly affected by the presence or absence of adenosine A1
receptors, but not of adenosine A2A receptors. Hz heterozygotes
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value of 44 nM. This is interesting in view of the fact that
in the same region most of the CGS 21680 binding can be
displaced by DPCPX in low nanomolar concentrations
(Johansson et al. 1993; Cunha et al. 1996).
Considering that high affinity interactions between [3H]
CGS 21680 and the adenosine A1 receptor are not seen in
all locations (for example, no binding could be detected in
the A2AR(−/−) striatum), it seems reasonable to assume
that such interactions, while dependent on A1 receptors,
also require some other protein. Given that most of the
[3H]CGS 21680 binding to hippocampus was unaffected
by eliminating A2A receptors by genetic means or by
blocking the receptors with antagonists we cannot explain
our data based on adenosine A1/A2A receptor heteromers.
Since the binding site we are studying is defined using
adenosine-like compounds and since the binding site
shows a pharmacology resembling an adenosine receptor,
the most parsimonious explanation is that this site
represents a particular conformation of the A1 receptor.
Whereas, the present results show that many of the
binding sites for [3H]CGS 21680 are not A2A receptors,
our results certainly do not question the presence of effects
mediated by A2A receptors outside the striatum. In fact,
there is evidence for A2A receptor mRNA in hippocampal
CA1 and CA3 pyramidal cells (Lopes et al. 2001) as well
as A2A receptor immunoreactivity, binding sites for [
3H]
SCH 58261 and functional receptors in hippocampal nerve
terminals (Rebola et al. 2002, 2003). Also glial cells
appear to express some A2A receptors (Kust et al. 1999;
Hettinger et al. 2001), and functional adenosine A2A
receptors have been found in astrocytes derived from the
rat hippocampus (Li 2001). Moreover, there are blood
vessels in the hippocampus, and like blood vessels
elsewhere (Ngai 2001; Lynge 2000) they express some
A2A receptors.
Both the mRNA (Fig. 1b) and the adenosine A2A
receptor protein (e.g., Rebola et al. 2003) are detected in
the hippocampus, although the receptor protein is
expressed at a concentration below the detection level
for the binding methods used here. Nevertheless, the
results obtained here with adenosine A1 and A2A receptor
knock-outs indicate that the vast majority of the sites with
which [3H]CGS 21680 interacts in the hippocampus are
not A2A receptors. Consequently, some of the literature
implicating A2A receptors in extrastriatal regions of the
brain that is predominantly based on studies with CGS
21680 may need to be reconsidered.
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